TREATMENT DISRUPTION AMONG PATIENTS WITH PARKINSON’S DISEASE WITH PSYCHOSIS ENROLLED IN US CENTERS FOR MEDICARE SERVICES

Author(s)

Graham C1, Kwiatkowski H2, Mitchell BP3, Shim A4
1PAREXEL Intermational, Portland, ME, USA, 2PAREXEL International, Carrboro, NC, USA, 3PAREXEL Intermational, Sioux Falls, SD, USA, 4ACADIA Pharmaceuticals Inc., San Diego, CA, USA

OBJECTIVES: Antipsychotic (AP) treatment is used to reduce psychotic symptoms among Parkinson’s disease psychosis (PDP) patients. This study identified characteristics and factors associated with treatment disruption among US Medicare PDP patients.

METHODS: Parkinson’s disease (PD) patients were identified during 2012-2015 using ICD-9 diagnosis codes from the Medicare database. PDP patients were identified after PD diagnosis and required to have two AP prescription claims (1st AP claim was index date). PDP patients were required to have 6 months of pre-index and 12 months of post-index data. During post-index, treatment disruption was defined as patients either discontinued (>30 days gap between AP fills) or were sporadic (>30 days gaps, on-off). Descriptive statistics and multivariate analysis was conducted to identify factors associated with the treatment disruptions.

RESULTS: Of 116,029 PD patients, 7,195 were identified as PDP patients. The PDP patients (mean age 80.3±7.5) had higher rates of dementia vs other PD patients (24.1% vs 60.4%) and depression (9.9% vs 18.8%), respectively. In the PDP group, 33.5% were continuers; 52.0% were discontinuers; and 14.5% were sporadic AP users during post-index. Gender, diabetes, malignancy, hypertension, prior skilled nursing facility, and use of aripiprazole, quetiapine and risperidone were found to be statistically different between continuers and discontinuers. There were similar findings between continuers and sporadic users; however, age, depression, and olanzapine use were additionally identified. Factors associated with AP discontinuation were; diabetes (OR 1.155, 95% CI 1.026, 1.301), any malignancy (OR 1.235, 95% CI 1.042, 1.465), and hypertension (OR 1.230, 95% CI 1.091, 1.386). In sporadic AP users, depression was also associated with discontinuation (OR 1.364, 95% CI 1.105, 1.683).

CONCLUSIONS: There is significant off-label use of AP treatment within the PDP population and a high percentage of treatment disruption was shown in this database review. This signifies an unmet need and suboptimal treatment since disruption is prevalent.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PMH68

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Mental Health, Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×